PT2919796T - Use of akkermansia for treating metabolic disorders - Google Patents

Use of akkermansia for treating metabolic disorders

Info

Publication number
PT2919796T
PT2919796T PT137920062T PT13792006T PT2919796T PT 2919796 T PT2919796 T PT 2919796T PT 137920062 T PT137920062 T PT 137920062T PT 13792006 T PT13792006 T PT 13792006T PT 2919796 T PT2919796 T PT 2919796T
Authority
PT
Portugal
Prior art keywords
akkermansia
metabolic disorders
treating metabolic
treating
disorders
Prior art date
Application number
PT137920062T
Other languages
Portuguese (pt)
Original Assignee
Univ Catholique Louvain
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2919796(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Catholique Louvain, Univ Wageningen filed Critical Univ Catholique Louvain
Publication of PT2919796T publication Critical patent/PT2919796T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
PT137920062T 2012-11-19 2013-11-15 Use of akkermansia for treating metabolic disorders PT2919796T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/073011 WO2014075745A1 (en) 2012-11-19 2012-11-19 Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
PT2919796T true PT2919796T (en) 2021-06-02

Family

ID=47257788

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137920062T PT2919796T (en) 2012-11-19 2013-11-15 Use of akkermansia for treating metabolic disorders

Country Status (14)

Country Link
US (8) US20150306152A1 (en)
JP (2) JP6426616B2 (en)
KR (4) KR102581171B1 (en)
CN (2) CN104918626B (en)
AU (1) AU2013346726B2 (en)
BR (1) BR112015011403A2 (en)
CA (1) CA2891758C (en)
DK (1) DK2919796T3 (en)
EA (2) EA037315B1 (en)
ES (1) ES2871817T3 (en)
HK (1) HK1215375A1 (en)
MX (1) MX365835B (en)
PT (1) PT2919796T (en)
WO (2) WO2014075745A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
KR101740893B1 (en) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 COMPOSITION COMPRISING EXTRACELLULAR VESICLES DERIVED FROM Akkermansia muciniphila AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING METABOLIC DISEASE
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
LT3065748T (en) 2014-12-23 2018-03-12 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
CN107849093B (en) 2015-05-06 2022-02-18 瓦赫宁恩大学 Method for culturing Ackermanella
CN107980043B (en) * 2015-05-06 2021-09-24 瓦赫宁恩大学 Use of polypeptides for the production of a medicament acting on immune signal transduction and/or influencing intestinal barrier function and/or regulating metabolic state
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA51639A (en) 2015-06-15 2020-04-15 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
PE20180242A1 (en) 2015-06-15 2018-01-31 4D Pharma Res Ltd COMPOSITIONS INCLUDING BACTERIAL STRAINS
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
DK3307288T3 (en) 2015-06-15 2019-10-07 4D Pharma Res Ltd COMPOSITIONS COMPREHENSIVE BAKERY STUES
CN105106245A (en) * 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Application of Akkermansia muciniphila BAA-835 strain
CN105030841A (en) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Application of Akkermansia muciniphila BAA-835 strain
BR112018004532B1 (en) 2015-09-10 2022-03-15 Université Catholique de Louvain Use of pasteurized akkermansia for the treatment of metabolic disorders
JP2018534277A (en) * 2015-10-05 2018-11-22 シュヴァイツェリッシェ フォルシュングスインスティテュート フュア ホーフゲブリクスクリーマ ウント メディツィン イン ダヴォス Use of Akkermansia muciniphila for treating inflammatory conditions
WO2017060491A1 (en) * 2015-10-09 2017-04-13 Biogaia Ab Mucus thickness to prevent diseases
CN105176822B (en) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 A kind of optimization separation method of human intestine probiotics
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
DK3209310T3 (en) 2015-11-20 2018-04-16 4D Pharma Res Ltd COMPOSITIONS COMPREHENSIVE BAKERY STUES
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HUE063584T2 (en) 2016-02-04 2024-01-28 Univ Gent Use of microbial communities for human and animal health
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP4249053A3 (en) 2016-03-04 2024-06-19 The Regents of The University of California Microbial consortium and uses thereof
AU2017226831B2 (en) 2016-03-04 2018-10-04 4D Pharma Plc Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
WO2017178496A1 (en) * 2016-04-11 2017-10-19 Wageningen Universiteit Novel bacterial species
US20190314425A1 (en) * 2016-07-11 2019-10-17 Korea Research Institute Of Bioscience And Biotechnology Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
CN109874329B (en) * 2016-08-12 2023-08-29 深圳华大生命科学研究院 Fusarium butyricum and culture method and application thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN110325196A (en) * 2016-12-20 2019-10-11 加利福尼亚大学董事会 For inhibiting the composition and method of epileptic attack
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
FR3065643B1 (en) 2017-04-26 2020-04-17 Usines Chimiques D'ivry La Bataille (Ucib) NUTRACEUTICAL AND / OR PHARMACEUTICAL COMPOSITION FOR STIMULATING THE PRODUCTION OF TYPE 2 BETA-DEFENSINS
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
PT3630136T (en) 2017-05-22 2021-06-11 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
BR112019026677A2 (en) 2017-06-14 2020-06-30 4D Pharma Research Limited compositions comprising bacterial strains
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
TWI640314B (en) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 Use of parabacteroides goldsteinii for reducing insulin resistance and improving glucose tolerance
TWI636788B (en) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 Use of parabacteroides goldsteinii to treat fatty liver disease
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
JP7171602B2 (en) * 2017-11-08 2022-11-15 アサヒグループホールディングス株式会社 Akkermansia muciniphila propagating material
EP3716983A4 (en) * 2017-11-30 2022-03-02 Glycom A/S Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation
JP7175990B2 (en) * 2018-03-02 2022-11-21 アカデミッシュ メディッシュ セントラム Fecal material for prevention or treatment of autoimmune disease
EP3773645A4 (en) 2018-04-10 2021-11-24 Siolta Therapeutics, Inc. Microbial consortia
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (en) * 2018-04-19 2021-03-10 주식회사 고바이오랩 Composition for preventing or treating immunometabolic diseases comprising Bacteroides vulgates
US20210222180A1 (en) * 2018-05-15 2021-07-22 Duke University Systems and methods for genetic manipulation of akkermansia species
CN110496140B (en) * 2018-05-18 2022-05-31 瑞微（深圳）生物科技有限公司 Application of bacteroides fragilis or Ackmann myxobacterium in preparation of drugs for preventing or treating tumors
US20210364526A1 (en) * 2018-05-23 2021-11-25 The Regents Of The University Of California Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
AU2019324734A1 (en) * 2018-08-20 2021-02-25 Murdoch Childrens Research Institute Behavioural treatment
CN110964650B (en) 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 Bacterial strain for preventing and treating metabolic diseases and application thereof
WO2020071660A1 (en) * 2018-10-01 2020-04-09 한국생명공학연구원 Anti-aging composition containing akkermansia muciniphila strain or culture thereof as active ingredient
KR102197180B1 (en) * 2018-10-11 2020-12-31 주식회사 고바이오랩 Akkermansia muciniphila and composition for controlling appetite or preventing, improving, relieving and treating metabolic disease comprising the same
WO2020076136A2 (en) * 2018-10-11 2020-04-16 서울대학교산학협력단 Akkermansia muciniphila strain and use thereof
ES2970821T3 (en) * 2018-12-21 2024-05-30 Salomon Amar Use of Akkermansia in the treatment of oral diseases
US20220289791A1 (en) * 2019-05-02 2022-09-15 Université Catholique de Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
JP7402629B2 (en) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 Composition containing propionic acid bacteria fermented product
TWI719549B (en) * 2019-07-22 2021-02-21 大江生醫股份有限公司 Prebiotic composition for promoting growth of akkermansia muciniphila
KR102128289B1 (en) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK27 strain AND uses thereof
KR102128287B1 (en) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK19 strain AND uses thereof
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
KR102397916B1 (en) * 2019-10-01 2022-05-17 (주)헬스바이옴 A novel anaerobic microbe isolated from human milk and method of preventing or treating metabolic disease using thereof
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
CN110698547B (en) * 2019-10-31 2023-01-03 南京农业大学 Recombinant expression Ackermanella membrane protein Amuc _1100 and application thereof
CN110786376A (en) * 2019-11-07 2020-02-14 中南大学湘雅医院 Application of inactivated akkermansia muciniphila in preparation of yogurt, and preparation method and application of yogurt
CN111202752A (en) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 Ackermanella compositions
CN111228315A (en) 2020-02-27 2020-06-05 上海上药信谊药厂有限公司 Antitumor composition
CN111450233B (en) * 2020-03-19 2021-04-13 中国农业大学 Application of microbial metabolite in relieving glycolipid metabolic disorder
KR102671044B1 (en) * 2020-03-25 2024-05-31 한국생명공학연구원 TARS or its fragments from Akkermansia muciniphila and uses thereof
CN115698043A (en) * 2020-04-24 2023-02-03 Ko生物技术有限公司 Protein variants having GLP-1 inducing activity and uses thereof
CN111996267A (en) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 Fluorescent quantitative PCR (polymerase chain reaction) primer group and kit for rapidly detecting AKK (alkyl ketene dimer) bacteria and application of fluorescent quantitative PCR primer group and kit
KR102185827B1 (en) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 Pharmaceutical composition for preventing or treating atopic disease comprising akkermansia muciniphila strain
BE1028339B1 (en) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprising Akkermansia muciniphila and green tea extract
CN113116936A (en) * 2021-04-02 2021-07-16 上海市第六人民医院 Application of akkermansia muciniphila in preparation of beta-chenodeoxycholic acid inhibitor
CN113322202B (en) * 2021-05-31 2022-03-01 君维安(武汉)生命科技有限公司 Ackermanella, culture method and application thereof
JP7398714B2 (en) * 2021-06-28 2023-12-15 東栄新薬株式会社 Akkermansia muciniphila proliferation-promoting composition applicable to medical and beauty treatments, as well as pharmaceuticals, food and beverages, and feed containing the same
CN113862193B (en) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 Acremonium muciniphilum and application thereof in preparation of antitumor drugs
AU2022386238A1 (en) * 2021-11-12 2024-06-27 Gelesis, Llc Compositions and methods for modulating the intestinal microbiome
WO2023178194A2 (en) * 2022-03-15 2023-09-21 Pendulum Therapeutics, Inc. Novel microbial composition and methods of use thereof
CN114949002B (en) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 Application of akkermansia muciniphila in preparation of composition for preventing and treating atherosclerosis
CN114949003B (en) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 Acremonium muciniphilum, application and culture method thereof
CN116115647A (en) * 2022-06-08 2023-05-16 广州知易生物科技有限公司 Application of akkermansia muciniphila in preparation of pharmaceutical composition or health-care product composition for improving metabolic syndrome
CN115252651B (en) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 Application of akkermansia muciniphila in preparation of composition for preventing and treating hypertension and composition containing same
CN115463159A (en) * 2022-09-26 2022-12-13 暨南大学附属第一医院（广州华侨医院） Application of Acermanium and Acermanium postbiotic in preparation of medicine or health-care product for preventing or treating hepatic steatosis
CN115747357A (en) * 2022-11-15 2023-03-07 迪辅乐生物(上海)有限公司 Detection kit and detection method for intestinal mucinous-Ackermanella
WO2024134035A1 (en) * 2022-12-22 2024-06-27 Sorbonne Universite Composition and use of turicimonas muris for the treatment of metabolic diseases
CN116077536B (en) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof
CN117603884B (en) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 Acremonium muciniphilum bacterial powder and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
AU2011223049B2 (en) 2010-03-01 2015-06-18 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
WO2013130773A2 (en) * 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders

Also Published As

Publication number Publication date
US20150306152A1 (en) 2015-10-29
AU2013346726A1 (en) 2015-06-04
KR20230080492A (en) 2023-06-07
EA037315B1 (en) 2021-03-11
WO2014075745A1 (en) 2014-05-22
KR20150093711A (en) 2015-08-18
KR102581171B1 (en) 2023-09-21
US20190282630A1 (en) 2019-09-19
HK1215375A1 (en) 2016-08-26
JP6426616B2 (en) 2018-11-21
CN104918626A (en) 2015-09-16
CN104918626B (en) 2020-07-07
US20200237832A1 (en) 2020-07-30
MX365835B (en) 2019-06-17
US20210322489A1 (en) 2021-10-21
EA202100040A3 (en) 2021-10-29
KR102297388B1 (en) 2021-09-03
JP2019048825A (en) 2019-03-28
US20200121737A1 (en) 2020-04-23
WO2014076246A1 (en) 2014-05-22
ES2871817T3 (en) 2021-11-02
CA2891758C (en) 2022-06-07
CN111603488B (en) 2024-04-05
KR20210111871A (en) 2021-09-13
AU2013346726B2 (en) 2017-11-02
BR112015011403A2 (en) 2018-02-06
CN111603488A (en) 2020-09-01
US20200237833A1 (en) 2020-07-30
EA202100040A2 (en) 2021-06-30
MX2015006234A (en) 2015-10-29
US20210393704A1 (en) 2021-12-23
EA201500535A1 (en) 2016-03-31
JP2016503418A (en) 2016-02-04
US20200155616A1 (en) 2020-05-21
KR20230121938A (en) 2023-08-21
DK2919796T3 (en) 2021-05-31
CA2891758A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
HK1215375A1 (en) Use of akkermansia for treating metabolic disorders
HK1206260A1 (en) Compositions and methods of use for treating metabolic disorders
HRP20180939T1 (en) Combination therapy for treatment of multiple sclerosis
HK1203830A1 (en) Compositions and methods for treating metabolic disorders
EP2852388A4 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
IL233506B (en) Biguanide compositions for treatment of metabolic disorders
IL226401A0 (en) Methods of treating fgf21-associated disorders
EP2723384A4 (en) Treatment of proteinopathies
IL225239A0 (en) Compositions for the treatment of acne and related disorders
PL2919796T3 (en) Use of akkermansia for treating metabolic disorders
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1204573A1 (en) Treatment of inflammatory skin disorders
EP2976094A4 (en) Methods of treating metabolic disorders
IL235317A0 (en) Composition for treating metabolic disorders
EP2709665A4 (en) Treatment of psoriasis
HK1219224A1 (en) Therapeutic agent for keratoconjunctive disorders
ZA201501038B (en) Treatment of wax
IL234616A0 (en) Herbal composition for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201201779D0 (en) Treatment of inflammatory disorders
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment